For the year ending 2025-12-31, GTBP has $8,106K in assets. $6,811K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6,811 | |||
| Restricted cash | 94 | |||
| Deferred offering costs | 634 | |||
| Prepaid expenses and other current assets | 567 | |||
| Total current assets | 8,106 | |||
| Total assets | 8,106 | |||
| Accounts payable | 748 | |||
| Accrued expenses | 1,560 | |||
| Warrant liability | 11 | |||
| Total current liabilities | 2,319 | |||
| Preferred stock value-Series CPreferred Stock | 1 | |||
| Common stock, par value 0.001, 250,000,000 shares authorized, 25,534,173 and 2,234,328 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 26 | |||
| Additional paid in capital | 729,661 | |||
| Accumulated deficit | -723,901 | |||
| Total stockholders equity (deficit) | 5,787 | |||
| Total liabilities and stockholders equity (deficit) | 8,106 | |||
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)